Generic Name and Formulations:
Progesterone (micronized) 100mg, 200mg; caps; contains peanut oil.
Virtus Pharmaceuticals, Inc.
Indications for PROMETRIUM:
To prevent endometrial hyperplasia in postmenopausal women with an intact uterus receiving conjugated estrogens. Secondary amenorrhea.
Endometrial hyperplasia prevention: 200mg once daily in the PM for 12 sequential days of each 28-day cycle. Amenorrhea: 400mg once daily in the PM for 10 days.
Undiagnosed vaginal bleeding. Breast or genital carcinoma. Severe liver dysfunction or disease. Missed abortion. Thrombophlebitis, thromboembolic disorders, cerebral apoplexy. Not for use as a diagnostic test for pregnancy. Peanut allergy. Pregnancy (Cat.B).
Conditions that may be aggravated by fluid retention. Renal or hepatic dysfunction. Depression. Discontinue if thrombotic disorders, papilledema, or retinal vascular lesions occur. Do initial and annual physical exam (include BP, PAP smear, mammogram). Discontinue pending exam if visual disturbances or migraine occurs. Monitor diabetics. Nursing mothers: not recommended.
Dizziness, mastodynia, headache, abdominal pain/bloating, fatigue, musculoskeletal pain, emotional lability, GI upset, vaginal discharge.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|